What is it?
Ibogaine is a powerful addiction interrupter from Tabernanthe iboga shrub. Central to Bwiti spiritual traditions for over 1000 years. Gabon declared it a National Treasure in 2000. **REQUIRES MEDICAL SUPERVISION** due to cardiac risks (QT prolongation).
**What is Ibogaine?**
Ibogaine (12-methoxyibogamine) is a monoterpenoid indole alkaloid with the molecular formula **C₂₀H₂₆N₂O**. It belongs to the class of "atypical psychedelics" or oneirogens—substances producing waking dream states rather than classical psychedelic visual effects.
The compound is extracted from *Tabernanthe iboga*, a rainforest shrub native to Gabon and Cameroon. Root bark contains approximately **1-6% ibogaine** along with a dozen related alkaloids including ibogaline, ibogamine, tabernanthine, and voacangine.
**Why microdosing differs from flood doses**: Traditional addiction treatment uses "flood doses" of **10-25 mg/kg** (typically 500-1,500+ mg total), producing intense 24-36 hour experiences requiring clinical supervision. Microdosing involves approximately **1-25 mg** (roughly 1% of flood dose), intended to provide subtle benefits without overwhelming psychoactive effects.
🚨 Important Warnings
Please read all warnings carefully before use.
NEVER use without medical supervision. EKG and medical clearance required. Cardiac monitoring essential. QT prolongation can persist up to 7 days.
Ibogaine resets opioid tolerance. Returning to previous opioid dose after treatment causes overdose. This is a major cause of post-treatment fatalities.
Absolute contraindications: prolonged QTc, heart disease, liver cirrhosis, schizophrenia, epilepsy, pregnancy. QTc ≥450ms (males) or ≥470ms (females) = exclusion.
CYP2D6 genotyping recommended. Poor metabolizers have 2-fold higher exposure and significantly elevated risk. Should receive at least half the intended dose.
If effects intensify at the same dose, this indicates noribogaine accumulation (half-life 24-50 hours). Reduce frequency or stop immediately.
⚠️ Interactions & Combinations
Important information about drug interactions and combinations. Always consult a physician before combining.
Cardiac medications
QT prolongation risk. Antiarrhythmics (amiodarone, sotalol, quinidine) are absolute contraindication. Fatal cardiac events documented.
SSRIs/SNRIs
CYP2D6 inhibition increases ibogaine exposure. Fluoxetine requires 5-6 week washout, other SSRIs 2-3 weeks.
MAOIs
Serotonin syndrome risk. Requires 7-14 day washout before ibogaine use.
Opioids
Ibogaine resets opioid tolerance to near-baseline. Post-treatment use at previous doses causes overdose. Methadone requires 7-14 day washout.
Lithium
Increased seizure risk when combined with psychedelics. Likely contraindication based on survey data.
Antipsychotics
QT prolongation risk. Haloperidol, ziprasidone, quetiapine are contraindicated.
Fluoroquinolones
QT prolongation risk with levofloxacin, moxifloxacin. Avoid concurrent use.
Benzodiazepines
Do NOT discontinue if dependent—withdrawal seizures during QT prolongation can be fatal. Maintain stable dose throughout treatment.
💊 Dosage Guidelines
Typical dosage ranges from sub-perceptual microdoses to full psychoactive doses
Microdose
5.0 mg
Sub-perceptual
📋 Microdosing Protocols
Recommended protocols and regimens for microdosing this substance.
Fadiman Protocol (Adapted)
Dosage:
- Root Bark: Not recommended (variable potency)
- Ibogaine Hcl: 10-25 mg
- Total Alkaloid: 50-100 mg
Schedule:
Day 1: microdose, Day 2-3: off, repeat
Adaptation of the classic Fadiman protocol for ibogaine. The longer off-days help prevent noribogaine accumulation due to its 24-50 hour half-life. Requires cardiac screening before starting.
Daily Low-Dose Protocol
Dosage:
- Timing: Morning and evening
- Ibogaine Hcl: 4 mg twice daily (8 mg total)
Schedule:
4 mg twice daily
Based on published case report (DOI: 10.47626/1516-4446-2021-2359). Patient with bipolar depression took 4 mg ibogaine HCl twice daily for 60 days, showing 85-90% reduction in depression/anxiety scores.
Post-Flood Maintenance
Dosage:
- Adjustment: Reduce frequency if effects accumulate
- Ibogaine Hcl: 10-20 mg daily
Schedule:
10-20 mg daily or every other day
For individuals who have completed flood-dose treatment seeking to maintain benefits and manage cravings. Helps sustain anti-addiction effects during integration period.
✨ Reported Effects
Deep Introspection
Heightened self-reflection and access to autobiographical memories at sub-threshold doses
Mood Enhancement
Antidepressant effects linked to GDNF upregulation and 5-HT2A activity reported in low-dose use
Cognitive Clarity
Improved mental clarity and reduced cognitive fog reported by some microdosers
Increased Energy
Mild stimulant-like alertness and motivation without perceptual disruption at microdose levels
Neuroplasticity Support
GDNF and BDNF upregulation supports neural repair and resilience, relevant to addiction and depression research
⚠️ Safety Information
Ibogaine carries serious cardiac risks — prior ECG screening is mandatory. Never use without medical supervision. Contraindicated with opioids, SSRIs, MAOIs, stimulants, and most psychiatric medications. Has life-threatening interactions with many common substances. Duration is 24–36 hours, requiring a fully dedicated, supervised setting. Not appropriate for self-administration under any circumstances.
🔬 Scientific Research
Current research findings and clinical studies.
60-80% reduction in withdrawal symptoms. Single dose can interrupt opioid addiction. Requires integration therapy.
Stanford 2024: 30 veterans with TBI. PTSD reduction Cohen's d=2.54, depression d=2.80. Suicidal ideation reduced from 47% to 7%. No serious cardiac events with magnesium protocol.
Netherlands 2022: 14 opioid-dependent patients. 11/14 did not return to morphine within 24h. QTc prolongation averaged 95ms, 50% exceeded 500ms threshold.
2022 review of 24 studies (705 individuals): Ibogaine reduces withdrawal symptoms and craving. Beneficial for depression and trauma symptoms.
Case study: 4mg ibogaine HCl twice daily for 60 days for bipolar depression showed 85-90% reduction in depression/anxiety scores.
Tabernanthalog (TBG) and oxa-iboga compounds show anti-addiction effects without cardiotoxicity. TBG has 100-fold less hERG potency.
⚖️ Legal Status
Current legal status in various jurisdictions. Always respect local laws.
| Jurisdiction | Status | Details |
|---|---|---|
| US |
Schedule I
|
Illegal federally. Texas allocated $50M for FDA clinical research (2025). Arizona also funding research. |
| Canada |
Prescription Drug List
|
Special Access Program available but rarely granted. |
| Mexico |
Unregulated
|
Full legal clinic access. Popular destination for ibogaine treatment. |
| New Zealand |
Prescription medicine
|
Unique globally—can be prescribed by registered physicians. |
| Netherlands |
Unregulated (gray area)
|
Clinics operate with legal uncertainty after court cases. |
| Czech Republic |
Unscheduled
|
Not specifically scheduled. Personal possession not criminal. |
| UK |
Psychoactive Substances Act 2016
|
Possession legal; supply illegal. |
| France |
Illegal
|
Controlled substance since 2007. |
| Portugal |
Decriminalized
|
Personal use only. |
| Australia |
Schedule 9 (prohibited)
|
Research only. |
| Brazil |
Prescription access
|
Available in hospital settings (São Paulo). |
| Costa Rica |
Unregulated
|
Clinics operate legally. |
| South Africa |
Schedule 6
|
Prescription with oversight. |
| Gabon |
National Treasure
|
Culturally protected since 2000. Country of origin. |
👤 Key Figures
Notable figures associated with the research and history of this substance.
Bwiti tradition
Indigenous spiritual practice
1000+ years of traditional use in Gabon. Practiced by Babongo, Mitsogo, and Fang peoples.
Howard Lotsof (1943-2010)
Advocate, researcher
Discovered ibogaine's anti-addiction properties at age 19. Founded NDA International (1986), obtained multiple patents, co-authored 60+ scientific papers.
Claudio Naranjo (1932-2019)
Psychiatrist, researcher
First to systematically study ibogaine's psychotherapeutic applications (1960s). Author of "The Healing Journey" (1973). Classified ibogaine as a "fantasy-enhancer".
Deborah Mash, Ph.D.
Neurologist, researcher
First FDA approval for human trials (1993-1994). Established Healing Visions clinic (St. Kitts, 300+ patients). Discovered noribogaine as active metabolite. Founded DemeRx.
Stanley Glick, M.D., Ph.D.
Neuroscientist
Foundational animal research on reducing self-administration of morphine, cocaine, alcohol, nicotine. Co-developed 18-methoxycoronaridine (18-MC), a safer synthetic analog.
Kenneth Alper, M.D.
Psychiatrist, researcher (NYU)
Collaborated with Lotsof for decades. Co-organized First International Conference on Ibogaine (NYU, 1999). Published first case series on ibogaine for heroin detox.
Thomas Kingsley Brown, Ph.D.
Researcher
Led MAPS-sponsored observational study (2010-2017) on long-term outcomes in Mexico. Published first prospective study of drug use outcomes with ibogaine.
Important Legal Notice
⚠️ Personal Responsibility
You use this application entirely at your own risk and responsibility. MicrodosingDiary is only a tool for recording personal experiences.
🚫 Not a Medical Service
This application IS NOT a medical tool, does not provide medical advice, does not diagnose or treat any conditions. Always consult a qualified physician.
⚖️ Legislation and Laws
Many substances used for microdosing are illegal in many countries. Users are fully responsible for complying with local laws. The application does not support or promote illegal activity.
❌ No Guarantees
We provide no guarantees regarding results, safety or efficacy of microdosing. All information is for informational purposes only.
🔞 Age Restriction
Application is intended only for persons over 18 years of age. By using the application you confirm that you are an adult.
🔒 Data Privacy
Your data is private and encrypted. We never share it with third parties without your consent. Application is for personal use only.
By using this application you accept all the above risks and waive any claims against the application operator.